DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
出版年份 2020 全文链接
标题
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-07-16
DOI
10.1186/s13045-020-00928-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
- (2020) Yonghan He et al. Nature Communications
- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The curcumin analog EF24 is a novel senolytic agent
- (2019) Wen Li et al. Aging-US
- A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
- (2019) Sajid Khan et al. NATURE MEDICINE
- Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models
- (2018) Samuel Y. Ng et al. Nature Communications
- Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
- (2018) Raphael Koch et al. BLOOD
- Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
- (2017) Ian Churcher JOURNAL OF MEDICINAL CHEMISTRY
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies
- (2017) Steven Grant LEUKEMIA & LYMPHOMA
- Pathways and mechanisms of venetoclax resistance
- (2017) Prithviraj Bose et al. LEUKEMIA & LYMPHOMA
- Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia
- (2017) Sonali P. Barwe et al. SEMINARS IN ONCOLOGY
- Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
- (2016) Nobumichi Ohoka et al. CURRENT CANCER DRUG TARGETS
- Chemical genetics approaches for selective intervention in epigenetics
- (2016) Andrew C Runcie et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project
- (2016) A. M. Perry et al. HAEMATOLOGICA
- Microenvironmental cues for T-cell acute lymphoblastic leukemia development
- (2016) Diana Passaro et al. IMMUNOLOGICAL REVIEWS
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project
- (2016) A. M. Perry et al. HAEMATOLOGICA
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
- (2015) Ashton C. Lai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
- (2015) Owen A. O'Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- Prime time for PROTACs
- (2015) Raymond J Deshaies Nature Chemical Biology
- Catalytic in vivo protein knockdown by small-molecule PROTACs
- (2015) Daniel P Bondeson et al. Nature Chemical Biology
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- How I treat the peripheral T-cell lymphomas
- (2014) A. J. Moskowitz et al. BLOOD
- Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia
- (2014) Aksana Kaefer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
- (2013) Vivien Mak et al. JOURNAL OF CLINICAL ONCOLOGY
- Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
- (2011) S. M. Schoenwaelder et al. BLOOD
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now